Article Figures & Data
Figures
- Figure 1.
Rosiglitazone and Bone Fracture Risk in Women with T2DM.
Reprinted from The Lancet. Volume 373, Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicenter, randomized, open-label trial, RECORD Study Group, pages 2125–2135, Copyright 2009, with permission from Elsevier.
Tools
Table of contents
Cited By...
- No citing articles found.